• 27 Mar 2026
• Admin
• News Article

India’s Semaglutide Race Heats Up: USV Launches “usema”

India’s diabetes crisis isn’t slowing down. With 100+ million people living with diabetes, access to advanced therapies is no longer optional—it’s urgent.

Now, USV Private Limited is stepping in with a major move. The company has launched usema, an injectable semaglutide, in collaboration with Dr. Reddy’s Laboratories.

What Makes “usema” Important?

This isn’t just another product launch. It’s among the first injectable semaglutide therapies approved by the Drugs Controller General of India (DCGI).

What’s available:

• 2 mg injection pen
• 4 mg injection pen
• 8 mg pen (coming soon)

Indication:

• Type 2 diabetes
• Associated metabolic conditions

Semaglutide has already proven its value globally. The gap in India has been access and affordability. That’s exactly what USV is targeting.

Built for Scale: Manufacturing and Access

USV is positioning usema as a locally manufactured, globally compliant alternative.

Key highlights:

• Manufactured in India
• Bioequivalent to the innovator molecule
• Backed by:
  • Integrated manufacturing
  • Cold-chain infrastructure
  • Established safety and efficacy data

The strategy is clear: bring a high-demand therapy to a much wider patient base.

Strategic Positioning: Strengthening Diabetes Leadership

USV isn’t new to this space.

The company already leads India’s:

• Oral anti-diabetic segment
• Cardiology prescriptions market

Its portfolio includes established brands like:

• Glycomet
• Ecosprin

Adding semaglutide strengthens its shift from traditional oral therapies → advanced injectables and metabolic care.

The Bigger Play: Beyond Just Diabetes

This launch fits into a broader transformation. USV is expanding into:

• Metabolic health
• Preventive care
• Nutraceuticals (via its Wellbeing Nutrition acquisition)

According to Managing Director Prashant Tewari: The goal is simple: improve outcomes while making advanced therapies accessible. That last part matters most in India.

Why This Launch Matters Now?

India is at an inflection point:

• Diabetes prevalence is exploding
• Obesity and metabolic disorders are rising
• Demand for GLP-1 therapies (like semaglutide) is surging

Until recently, these therapies were:

• Expensive
• Limited in availability
• Concentrated in urban markets

A domestic player entering this space could reshape access dynamics.

Final Take

This isn’t just a product launch—it’s a market signal.

• Semaglutide is moving mainstream in India
• Local manufacturing is driving affordability
• Competition in GLP-1 therapies is about to intensify

If USV executes well, usema could become a defining brand in India’s metabolic care landscape.